基因科学寻求中国对SIRT6基因变异的专利批准,以治疗NASH,推动其全球治疗发展。 Genflow Biosciences seeks Chinese patent approval for SIRT6 gene variants to treat NASH, advancing its global therapy development.

以长寿为重点的一家欧洲生物技术公司,即Genflow Biosciences公司,已请求在中国对专利性SIRT6基因变异物进行专利审查,这些基因变异物针对的是非甲型肝炎(NASH),这是一种严重的肝病,治疗途径有限。 Genflow Biosciences, a European longevity-focused biotech company, has requested patent examination in China for proprietary SIRT6 gene variants targeting Non-Alcoholic Steatohepatitis (NASH), a serious liver disease with limited treatment options. 该举措加强了其全球知识产权组合,并强调其致力于为世界各地的患者开发创新疗法。 The move strengthens its global intellectual property portfolio and underscores its commitment to developing innovative therapies for patients worldwide.